TELA Bio, Inc.

NasdaqGM:TELA Stock Report

Market Cap: US$80.7m

TELA Bio (TELA) Stock Overview

A commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. More details

TELA fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Earnings are forecast to grow 69% per year

Trading at good value compared to peers and industry

Risk Analysis

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($81M)

Volatile share price over the past 3 months compared to the US market


TELA Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

INBS logo
Intelligent Bio Solutions
JO
Jolt_Communications
Community Contributor

The Future of Drug Testing? Fingerprint Tech Shows Serious Promise

Key Takeaways Intelligent Bio Solutions has a new way to test for drugs using fingerprints: it’s quick, portable, and doesn’t require pee cups or saliva swabs. With commercial traction in 24 countries and over 450 active accounts, INBS is now targeting the U.S. market, where over 55 million drug tests are performed annually.
View narrative
US$2.98
FV
40.3% undervalued intrinsic discount
59.20%
Revenue growth p.a.
9users have liked this narrative
0users have commented on this narrative
48users have followed this narrative
28 days ago author updated this narrative

TELA Bio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for TELA Bio
Historical stock prices
Current Share PriceUS$2.04
52 Week HighUS$5.18
52 Week LowUS$0.86
Beta0.79
1 Month Change29.94%
3 Month Change88.89%
1 Year Change-53.10%
3 Year Change-74.44%
5 Year Change-84.37%
Change since IPO-84.72%

Recent News & Updates

Investors Still Aren't Entirely Convinced By TELA Bio, Inc.'s (NASDAQ:TELA) Revenues Despite 39% Price Jump

May 21
Investors Still Aren't Entirely Convinced By TELA Bio, Inc.'s (NASDAQ:TELA) Revenues Despite 39% Price Jump

Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 50%

Mar 31
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 50%

Recent updates

Investors Still Aren't Entirely Convinced By TELA Bio, Inc.'s (NASDAQ:TELA) Revenues Despite 39% Price Jump

May 21
Investors Still Aren't Entirely Convinced By TELA Bio, Inc.'s (NASDAQ:TELA) Revenues Despite 39% Price Jump

Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 50%

Mar 31
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 50%

Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely

Nov 09
Even With A 27% Surge, Cautious Investors Are Not Rewarding TELA Bio, Inc.'s (NASDAQ:TELA) Performance Completely

Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%

Aug 19
Not Many Are Piling Into TELA Bio, Inc. (NASDAQ:TELA) Stock Yet As It Plummets 33%

Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?

Jul 03
Does TELA Bio (NASDAQ:TELA) Have A Healthy Balance Sheet?

Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

May 29
Shareholders May Be More Conservative With TELA Bio, Inc.'s (NASDAQ:TELA) CEO Compensation For Now

TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

May 23
TELA Bio, Inc. (NASDAQ:TELA) Soars 31% But It's A Story Of Risk Vs Reward

Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 24
Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

Mar 08
Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

Oct 07
TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

Jul 31
Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption

Oct 02

Tela Bio prices $32M common stock offering

Aug 16

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

May 12
Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

TELA Bio - Follow Up With Management

Jan 14

Our First Look At TELA Bio

Nov 04

TELA Bio Plugging Away

Oct 25

Shareholder Returns

TELAUS Medical EquipmentUS Market
7D10.3%1.1%2.1%
1Y-53.1%12.2%14.3%

Return vs Industry: TELA underperformed the US Medical Equipment industry which returned 11.9% over the past year.

Return vs Market: TELA underperformed the US Market which returned 13.2% over the past year.

Price Volatility

Is TELA's price volatile compared to industry and market?
TELA volatility
TELA Average Weekly Movement13.6%
Medical Equipment Industry Average Movement8.7%
Market Average Movement7.4%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market3.9%

Stable Share Price: TELA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: TELA's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2012209Antony Koblishwww.telabio.com

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States.

TELA Bio, Inc. Fundamentals Summary

How do TELA Bio's earnings and revenue compare to its market cap?
TELA fundamental statistics
Market capUS$80.69m
Earnings (TTM)-US$43.44m
Revenue (TTM)US$71.22m
1.1x
P/S Ratio
-1.9x
P/E Ratio

Is TELA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TELA income statement (TTM)
RevenueUS$71.22m
Cost of RevenueUS$23.17m
Gross ProfitUS$48.04m
Other ExpensesUS$91.49m
Earnings-US$43.44m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-1.10
Gross Margin67.46%
Net Profit Margin-61.00%
Debt/Equity Ratio227.7%

How did TELA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/03 07:21
End of Day Share Price 2025/07/03 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TELA Bio, Inc. is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William PlovanicCanaccord Genuity
Caitlin CroninCanaccord Genuity
David TurkalyCitizens JMP Securities, LLC